Anders Karlén is a professor of Computer-Aided Drug Design at Uppsala University and focuses on hit identification and lead development in antibacterial drug discovery.
His research group studies targets of importance in infectious diseases with a focus on Gram-negative infections. At Uppsala University, he is the overall medicinal chemistry project leader for drug discovery efforts directed at several different antibacterial targets.
Between 2014 and 2021, Anders has led the Managing Entity as well as been co-coordinator of the project from the Innovative Medicines Initiative (IMI) entitled European Gram-negative Antibacterial Engine (ENABLE). He is presently the coordinator of the ENABLE-2 project, a national extension of ENABLE. Since 2019, Anders has also coordinated the project within IMI’s Antimicrobial Resistance (AMR) Accelerator Programme entitled Collaboration for Prevention and Treatment of MDR Bacterial Infections (COMBINE).